Loss-Making Omeros Corporation (NASDAQ:OMER) Expected To Breakeven In The Medium-Term

We feel now is a pretty good time to analyse Omeros Corporation's (NASDAQ:OMER) business as it appears the company may be on the cusp of a considerable accomplishment. Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s loss has recently broadened since it announced a US$175m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$185m, moving it further away from breakeven. The most pressing concern for investors is Omeros' path to profitability – when will it breakeven? In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

View our latest analysis for Omeros

Omeros is bordering on breakeven, according to the 3 American Pharmaceuticals analysts. They expect the company to post a final loss in 2025, before turning a profit of US$54m in 2026. The company is therefore projected to breakeven just over a year from today. How fast will the company have to grow each year in order to reach the breakeven point by 2026? Working backwards from analyst estimates, it turns out that they expect the company to grow 56% year-on-year, on average, which is extremely buoyant. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

Underlying developments driving Omeros' growth isn’t the focus of this broad overview, however, take into account that typically pharmaceuticals, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

Before we wrap up, there’s one issue worth mentioning. Omeros currently has negative equity on its balance sheet. Accounting methods used to deal with losses accumulated over time can cause this to occur. This is because liabilities are carried forward into the future until it cancels. These losses tend to occur only on paper, however, in other cases it can be forewarning.

Next Steps:

There are too many aspects of Omeros to cover in one brief article, but the key fundamentals for the company can all be found in one place – Omeros' company page on Simply Wall St. We've also put together a list of relevant aspects you should look at:

1. Valuation: What is Omeros worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Omeros is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Omeros’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.